Brightsurf Science News & Current Events

December 10, 2017
Phase 2 CAR-T study reports significant remission rates at 15-month follow up
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta™).

Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia
Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorder
Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis.

Tracking how multiple myeloma evolves by sequencing DNA in the blood
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back.

Sequencing offers clues to progression toward multiple myeloma
Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms.

Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus host
Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

Landmark CAR-T cancer study published in the New England Journal of Medicine
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

CAR T, immunotherapy bring new hope for multiple myeloma patients
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies.

Global CAR T therapy trial shows high rates of durable remission for NHL
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

Dolphin and bear studies have paved the way to improved population forecasting
A new article by a UNSW Sydney-led team challenges the validity of current methods for forecasting the persistence of slow-growing species for conservation purposes, and provides a better approach to reducing the threat of extinction.

Targeted therapies show promise improving outcomes across several hematologic malignancies
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

NUS marine scientists lead comprehensive review of giant clams species worldwide
An international team of marine researchers, led by Dr Neo Mei Lin and Associate Professor Peter Todd from the National University of Singapore, has recently published a comprehensive study on the status of giant clams worldwide.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.